How do you pay?

How to pay the least

Ask for the cash price

Ninlaro

We didn’t find one.

  1. Ask your pharmacy for Ninlaro’s cash price, and one or two other pharmacies too.
  2. Ninlaro’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Takeda Oncology Patient Assistance Program (Takeda Oncology Here2Assist). To be eligible for the Patient Assistance Program, patients must meet certain financial and insurance coverage criteria. Or call 1-844-817-6468 (Option 2).

See if you qualify 

Compare every option

Question
Brand nameNinlaro
Authorized genericixazomib
Regular genericixazomib
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Ninlaro?
The original
–
–

Brand nameThe maker’s card

Takeda Oncology Co-Pay Assistance Program

Savings card from Takeda

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a prescription

Sign up on ninlaro.com 

Or call 1-844-817-6468.

In the maker’s words

“You could pay as little as $0 per prescription.”

From the maker’s offer on ninlaro.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Ninlaro itself, from the same company, sold without the brand name, and usually for less. For now Ninlaro is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

NINLARO is a proteasome inhibitor indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

Limitations of Use: NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.

Source: the FDA label for Ninlaro (Takeda Pharmaceuticals America, Inc.), August 11, 2026. Full label on DailyMed 

Good to know